Axsome Therapeutics Inc
AXSM
Get informed when a big investor buys or sells
+ FollowMarket Cap$7.62B
Close$
$23.38
83.9% downside
Current Fair Value
83.9% downsideOvervalued by 83.9% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.62 Billion |
|---|---|
| Enterprise Value | $7.52 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.68 |
| Beta | 0.6 |
| Outstanding Shares | 51,500,690 |
Return
| Return on Equity | -230.05% |
|---|---|
| Return on Assets | -25.17% |
| Return on Invested Capital | -57.44% |
Valuation & Multiples
| P/E Ratio | -38.68 |
|---|---|
| PEG | -555.36 |
| Price to Sales | 9.67 |
| Price to Book Ratio | 145.04 |
| Enterprise Value to Revenue | 9.68 |
| Enterprise Value to EBIT | -43.49 |
| Enterprise Value to Net Income | -40 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 2.63 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 10, 2026
EPS Estimate
$-0.89
Average shareholder expectationRevenue Estimate
$221.11 M
Average shareholder expectationNext Earnings Call
Expected Date
November 2, 2026
EPS Estimate
$-0.62
Average shareholder expectationRevenue Estimate
$250.22 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 110.31% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.88%▼ 74.42% |
|---|---|
| Total Invested | $82.84M▼ 99.12% |
| Investors Holding | 35▼ 505.00% |
ESG Score
No data
About Axsome Therapeutics Inc
712 employees
CEO: Herriot Tabuteau Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people facing unsatisfactory tre...